gM-negative EHV-mutants
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsKnut Elbers, Nikolaus Osterrieder, Christian Seyboldt
Life of this patent
Estimating the term…
Abstract
This invention relates to Equine Herpes Viruses (EHV) wherein the protein gM is essentially absent or modified and non-functional with respect to its immunomodulatory capacity. Further aspects of the invention relate to nucleic acids coding said viruses, pharmaceutical compositions comprising these viruses or nucleic acids and uses thereof. The invention also relates to methods for improving the immune response induced by an EHV vaccine against wild type EHV infections, methods for the prophylaxis and treatment of EHV infections and methods for distinguishing wild type EHV infected animals from animals treated with EHV's according to the invention.
Claims7
An Equine Herpes Virus wherein the nucleotide sequence encoding a protein gM is at least 80% absent and wherein the expression of the gene coding for the UL9 homolog (gene 53) is not affected.
An Equine Herpes Virus, wherein the nucleotides 93254 to 94264 as numbered for the virus strain EHV-1 Ab4p or corresponding thereto in other EHV strains are deleted.
Dependencies are inferred from the claim text.